Pharmaceutical Companies

Enhanced tariffs on pharma imports in the US can severely impact Indian drug manufacturers as it would lead to higher production costs, making shipments less competitive against products from other countries. Smaller drug firms operating on thin margins can face severe pressure potentially forcing consolidation or closure. The automobile sector, on the other hand, is expected to have a very minimal impact owing to the US being a small export market. Terming India as a very high tariff nation, US President Donald Trump has said that reciprocal tariffs on countries that impose levies on American goods will kick in on April 2. India currently levies around 10 per cent import duty on American drugs, while the US doesn't charge any import duty on Indian drugs. Shardul Amarchand Mangaldas & Co Partner Arvind Sharma said as of recent history, the US has been a net importer of pharmaceutical products to meet its domestic demand. "In the event the US decides to impose substantial tariffs

The regulatory body, which comes under the Department of Pharmaceuticals (DoP), took the decision to revise the prices of the formulations during the authority's 130th meeting on February 25

The US president has imposed a 10 per cent tariff across all Chinese imports into the US and proposed a 25 per cent levy on most goods from Mexico and Canada

Maharashtra's tax office has contended that the transfer of its pharma business to Piramal Pharma counts as an itemized sale and not a slump sale, the company said

India has also surpassed the US in the number of FDA-registered generic manufacturing sites

India, which calls itself the 'pharmacy of the world', makes cheaper generic versions of complex innovative drugs in its massive factory clusters and exports them to over 200 countries

It is expected that representatives for MSMEs pharma manufacturers may raise the issue of extension of Revised Schedule M implementation timelines

Indian pharmaceutical (IT) major, Dr Reddy's Laboratories, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Thursday, January 23, 2025

The flagship ICC in Bengaluru complements Takeda's existing centres in Slovakia and Mexico, highlighting its strategic focus on data and advanced digital technologies

The listing day performance was largely in line with the subscription levels for the threen IPOs

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children

India's pharmaceutical sector is targeting $130 billion by 2030 and biotechnology is aiming for $300 billion by the same year: Great Place To Work report

Bulk drug exports are expected to see moderate increases, supported by volume growth from new launches, customised synthesis, and rising demand for complex drugs

According to Bloomberg, 30 of 41 analysts are bullish on Sun Pharma, while the remaining seven have a neutral rating and only 4 are bearish

The National Green Tribunal has sought a response from the Hyderabad regional office of the Union Ministry of Environment Forest and Climate Change and others on the blast at a pharmaceutical company in Hyderabad last month that left one dead and three others injured. The green body was hearing a matter where it had taken suo motu (on its own) cognisance of a PTI report published on November 21 titled 'One dead, three injured in reactor blast at pharma company in Hyderabad.' In an order dated November 28, a bench of NGT Chairperson Justice Prakash Shrivastava said, "The news item relates to a flash fire triggered by a reactor blast at a pharmaceutical company in Hyderabad, resulting in the death of one man and injuries caused to three others. As per the article, the incident occurred while the four workers were repairing the reactor." The bench also comprising judicial member Justice Arun Kumar Tyagi and expert member A Senthil Vel said the news item did not indicate whether steps h

On a sequential basis, the company exhibited a 6.8 per cent rise in net profit, while its revenue grew by 5.5 per cent, from Rs 2,655 crore and Rs 12,380.7 crore reported in Q3 FY24, respectively

Cipla is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year on year basis and net profits seeing a mid single digit growth

The upcoming budget would be Modi's first major policy announcement in his third term as prime minister

Fourth largest IPO of 2024; company will use the proceeds to repay debt and for general corporate purposes

The companies said they have signed a long-term agreement to continue collaborating on the development of mRNA-based vaccines and a license that allows Emcure to use HDT's mRNA technology